Evidence map›Paper›PMID 42255980›Full record

ArticleClinical and translational radiation oncology2026

Definitive proton therapy for unresectable trunk soft tissue sarcoma: a single-institution prospective registry-based cohort study.

Shuou Sudo, Koichiro Nakajima, Hiroyuki Ogino, Yukihiro Yokoyama, Masaki Sunagawa, Hiromitsu Iwata, Yukiko Hattori, Kensuke Hayashi, Toshiyuki Toshito, Akio Hiwatashi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shuou SudoDepartment of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City University West Medical Center, Nagoya, Japan.
Koichiro NakajimaDepartment of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City University West Medical Center, Nagoya, Japan.
Hiroyuki OginoDepartment of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City University West Medical Center, Nagoya, Japan.
Yukihiro YokoyamaDivision of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Masaki SunagawaDivision of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hiromitsu IwataDepartment of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City University West Medical Center, Nagoya, Japan.
Yukiko HattoriDepartment of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City University West Medical Center, Nagoya, Japan.
Kensuke HayashiDepartment of Proton Therapy Technology, Nagoya Proton Therapy Center, Nagoya City West Medical Center, Nagoya, Japan.
Toshiyuki ToshitoDepartment of Proton Therapy Physics, Nagoya Proton Therapy Center, Nagoya, Japan.
Akio HiwatashiDepartment of Radiology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and purpose: Optimal management for locally confined unresectable trunk soft tissue sarcomas (STS) has not been established, and the role of radiotherapy remains unclear. We evaluated clinical outcomes and quality of life (QOL) after definitive proton therapy (PT). Materials and methods: We conducted a retrospective and single-institution review of patients with unresectable trunk STS treated with definitive PT, drawn from a prospective registry. Endpoints included overall survival (OS), local control (LC), progression-free survival (PFS), toxicity, and QOL. Results: Thirty-three patients were included. Median age was 61 years (range, 19-85). PT was most commonly delivered as 70.2 Gy (RBE) in 26 fractions (58%) or 60.8 Gy (RBE) in 16 fractions (30%). Spot scanning technique was used in 26 patients (79%). The most common histological subtype was dedifferentiated liposarcoma (42%). Median follow-up was 27 months (41.5 months for survivors). Three-year OS, LC, and PFS rates were 51% (95% CI: 31-68%), 81% (60-92%), and 39% (23-55%), respectively; median OS was 39 months. Gross tumor volume ≥300 cm Conclusion: Reports on PT for this disease are scarce. Our findings suggest that PT is a safe and effective treatment option for unresectable trunk STS. Given its favorable safety profile and dosimetric advantages, PT is well suited for multidisciplinary treatment strategies and should be actively considered for these patients.

Indexed as

LiposarcomaProton therapyQuality of lifeRetroperitoneal sarcomaSoft tissue sarcomaSpot scanning

Identifiers

PMID42255980
PMCPMC13241659

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.